News

Alta Partners Promotes Alison de Bord to Director

October 09, 2006

Adam Tomasi, Ph.D. joins as Kauffman Fellow

San Francisco, CA., October 9, 2006 – Alta Partners, a life sciences venture capital firm based in San Francisco, today announced that Alison de Bord has been promoted to Director. Alison joins Alta’s other six Directors responsible for investing Alta Partners VIII. She currently represents Alta as a Director on the boards of Aegerion Pharmaceuticals, Insulet and SurgRx, and was directly involved in Alta’s investments in Esperion Therapeutics and Kerberos Proximal Solutions.

“Over the past 5 years, Alison has proven to be a valued member of the Alta team. Building upon her life sciences banking and research experience, Alison has honed her investment skills here at Alta and developed terrific instincts,” said Guy Nohra, Managing Director at Alta Partners. “We are confident that Alison will continue to find promising investments for Alta, provide informed leadership for our companies and help the firm deliver strong returns for our investors.”

Alison was a Principal in Alta BioPharma III most recently, and joined Alta Partners as an Associate in 2001. Prior to Alta, Alison was a Senior Associate in Robertson Stephens’ Life Sciences Investment Banking Group with primary responsibilities for the execution of corporate finance transactions including IPOs, follow-on equity and convertible preferred offerings. Previously, she was an Associate in Robertson Stephens’ equity research group where she focused on growth medical technology companies. She began her career in the business development group at Geron, a biotechnology company. Alison earned a Master of Business Administration from Columbia Business School and a Bachelor of Arts in History from Colgate University.

In addition, Adam Tomasi, Ph.D. has joined the firm as a Kauffman fellow. Prior to joining Alta, Adam was a student in the Harvard-MIT Biomedical Enterprise Program and held lead scientific positions in medicinal chemistry at Cytokinetics and Gilead Sciences.

Adam completed his Ph.D. at UC Irvine where he was a Fellow of the American Chemical Society and the UC Regents. He continued his education with a postdoctoral role at The Scripps Research Institute/The Genomics Institute of the Novartis Foundation. Adam holds a B.S. in Chemistry from UC Berkeley, a Ph.D. in Chemistry from UC Irvine, and an MBA from MIT Sloan.

About Alta Partners

Alta Partners is a San Francisco-based venture capital firm focused on life sciences investing. Founded in 1996, the firm currently manages $2 billion in committed capital through eight venture fund programs. Alta invests in life sciences companies across the development continuum, from company formation to later-stage opportunities, and has funded more than 110 companies in the sector to date. www.altapartners.com